SUTRO BIOPHARMA, INC. Lease, Cost
SUTRO BIOPHARMA, INC. (STRO) reported Lease, Cost of $2.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. lease, cost for the quarter ending 2026-06-30 was $2.39M, a 13.54% decline year-over-year.
- SUTRO BIOPHARMA, INC. lease, cost for the quarter ending 2026-03-31 was $2.38M, a 13.30% decline year-over-year.
- SUTRO BIOPHARMA, INC. lease, cost for the quarter ending 2025-12-31 was $2.73M, a 2.43% decline year-over-year.
- SUTRO BIOPHARMA, INC. lease, cost for the quarter ending 2025-09-30 was $2.76M, a 1.66% increase year-over-year.
- SUTRO BIOPHARMA, INC. lease, cost for fiscal 2025 was $10.99M, a 0.20% decline from fiscal 2024.
- SUTRO BIOPHARMA, INC. lease, cost for fiscal 2024 was $11.01M, a 17.66% increase from fiscal 2023.
- SUTRO BIOPHARMA, INC. lease, cost for fiscal 2023 was $9.36M, a 19.30% increase from fiscal 2022.
- SUTRO BIOPHARMA, INC. lease, cost for fiscal 2022 was $7.85M, a 25.71% decline from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.39M 10-Q · filed 2026-08-12 | $4.77M 10-Q · filed 2026-08-12 | $7.49M derived: sum of 3 quarters · filed 2026-08-12 | $10.25M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $2.38M 10-Q · filed 2026-05-14 | $5.11M derived: sum of 2 quarters · filed 2026-05-14 | $7.86M derived: sum of 3 quarters · filed 2026-05-14 | $10.63M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $2.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $5.48M derived: sum of 2 quarters · filed 2026-03-23 | $8.25M derived: sum of 3 quarters · filed 2026-08-12 | $10.99M 10-K · filed 2026-03-23 |
| 2025-09-30 | $2.76M 10-Q · filed 2025-11-06 | $5.52M derived: sum of 2 quarters · filed 2026-08-12 | $8.27M 10-Q · filed 2025-11-06 | $11.06M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $2.76M 10-Q · filed 2026-08-12 | $5.51M 10-Q · filed 2026-08-12 | $8.30M derived: sum of 3 quarters · filed 2026-08-12 | $11.01M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $2.75M 10-Q · filed 2026-05-14 | $5.54M derived: sum of 2 quarters · filed 2026-05-14 | $8.25M derived: sum of 3 quarters · filed 2026-05-14 | $11.13M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $2.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $5.51M derived: sum of 2 quarters · filed 2026-03-23 | $8.38M derived: sum of 3 quarters · filed 2026-03-23 | $11.01M 10-K · filed 2026-03-23 |
| 2024-09-30 | $2.71M 10-Q · filed 2025-11-06 | $5.59M derived: sum of 2 quarters · filed 2025-11-06 | $8.22M 10-Q · filed 2025-11-06 | $10.99M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $2.88M 10-Q · filed 2025-08-07 | $5.51M 10-Q · filed 2025-08-07 | $8.28M derived: sum of 3 quarters · filed 2025-08-07 | $10.90M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $2.63M 10-Q · filed 2025-05-08 | $5.40M derived: sum of 2 quarters · filed 2025-05-08 | $8.02M derived: sum of 3 quarters · filed 2025-05-08 | $10.02M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $5.39M derived: sum of 2 quarters · filed 2025-03-13 | $7.39M derived: sum of 3 quarters · filed 2025-03-13 | $9.36M 10-K · filed 2025-03-13 |
| 2023-09-30 | $2.62M 10-Q · filed 2024-11-13 | $4.62M derived: sum of 2 quarters · filed 2024-11-13 | $6.59M 10-Q · filed 2024-11-13 | $8.58M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $2.00M 10-Q · filed 2024-08-13 | $3.97M 10-Q · filed 2024-08-13 | $5.96M derived: sum of 3 quarters · filed 2025-03-13 | $7.84M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $1.97M 10-Q · filed 2024-05-13 | $3.96M derived: sum of 2 quarters · filed 2025-03-13 | $5.85M derived: sum of 3 quarters · filed 2025-03-13 | $7.83M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $3.88M derived: sum of 2 quarters · filed 2025-03-13 | $5.86M derived: sum of 3 quarters · filed 2025-03-13 | $7.85M 10-K · filed 2025-03-13 |
| 2022-09-30 | $1.88M 10-Q · filed 2023-11-13 | $3.87M derived: sum of 2 quarters · filed 2023-11-13 | $5.85M 10-Q · filed 2023-11-13 | $8.43M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-06-30 | $1.99M 10-Q · filed 2023-08-10 | $3.97M 10-Q · filed 2023-08-10 | $6.55M derived: sum of 3 quarters · filed 2024-03-25 | $9.59M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-03-31 | $1.98M 10-Q · filed 2023-05-15 | $4.56M derived: sum of 2 quarters · filed 2024-03-25 | $7.60M derived: sum of 3 quarters · filed 2024-03-25 | $10.01M derived: sum of 4 quarters · filed 2024-03-25 |
| 2021-12-31 | $2.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $5.62M derived: sum of 2 quarters · filed 2024-03-25 | $8.03M derived: sum of 3 quarters · filed 2024-03-25 | $10.56M 10-K · filed 2024-03-25 |
| 2021-09-30 | $3.04M 10-Q · filed 2022-11-08 | $5.45M derived: sum of 2 quarters · filed 2022-11-08 | $7.98M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $2.40M 10-Q · filed 2022-08-08 | $4.84M 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $2.44M 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |